2016
DOI: 10.1194/jlr.m059113
|View full text |Cite
|
Sign up to set email alerts
|

FADS2 genotype regulates delta-6 desaturase activity and inflammation in human adipose tissue

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
36
0
1

Year Published

2016
2016
2022
2022

Publication Types

Select...
8
2

Relationship

2
8

Authors

Journals

citations
Cited by 50 publications
(41 citation statements)
references
References 34 publications
(37 reference statements)
3
36
0
1
Order By: Relevance
“…The higher plasma n-6/n-3 ratio is indicative of increased adipocyte proliferation and differentiation, lipogenesis and PPARγ signaling [49], as well as a more pro-inflammatory state. As eicosanoid levels derived from the n-3 and n-6 series are controlled by the rate-limiting steps catalyzed by D5D and D6D [50], the higher D6D index was also consistent with a pre-diabetic state because this activity correlates directly with diabetes risk and insulin resistance (whereas D5D activity has a reciprocal correlation; [51]) and with inflammatory marker IL-1β in both visceral and subcutaneous fat [23]. If this scenario is correct, the proteomics of non-visceral fat depots align more closely to the plasma FFA profile.…”
Section: Discussionmentioning
confidence: 95%
“…The higher plasma n-6/n-3 ratio is indicative of increased adipocyte proliferation and differentiation, lipogenesis and PPARγ signaling [49], as well as a more pro-inflammatory state. As eicosanoid levels derived from the n-3 and n-6 series are controlled by the rate-limiting steps catalyzed by D5D and D6D [50], the higher D6D index was also consistent with a pre-diabetic state because this activity correlates directly with diabetes risk and insulin resistance (whereas D5D activity has a reciprocal correlation; [51]) and with inflammatory marker IL-1β in both visceral and subcutaneous fat [23]. If this scenario is correct, the proteomics of non-visceral fat depots align more closely to the plasma FFA profile.…”
Section: Discussionmentioning
confidence: 95%
“…It is the rate-limiting metabolic enzyme in the conversions of linoleic acid into arachidonic acid (AA) and of α-linolenic acid into eicosapentanoic acid (EPA) (Park et al 2015). Both AA and EPA are involved in the inflammatory response (Vaittinen et al 2016). FADS2 activity is known to be increased in breast cancer; therefore, its inhibition is a potential treatment method (Lane et al 2003;Pender-Cudlip et al 2013).…”
Section: Resultsmentioning
confidence: 99%
“…FADS2 plays a pivotal role in the biosynthesis of polyunsaturated fatty acids [29][30][31][32]. Genome-wide association studies (GWAS) have confirmed the effects of FADS2 genetic variations on diseases related to lipid metabolism [33,34].…”
Section: Discussionmentioning
confidence: 99%